A relationship between drug-resistant epilepsy and structural abnormalities in neuroimaging

Alejandro Flores-Sobrecuevá, Santiago Paláu-Hernández, Juan L. Cruz-Rosales, Héctor G. Hernández-Rodríguez, Jorge G. Reyes-Vaca, Juan M. Shiguetomi-Medina, and Ildefonso Rodriguez-Leyva

1Neurology Service, Hospital Central “Dr. Ignacio Morones Prieto”; 2Faculty of Medicine, and 3Department of Public Health, Universidad Autónoma de San Luis Potosí, Mexico; 4Imagenology Service, Hospital Central “Dr. Ignacio Morones Prieto”; 5Department of Postgraduate Studies, Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico

Abstract

Background and objectives: The purpose of the study was to seek a relationship between drug-resistant epilepsy and structural alterations in neuroimaging to strengthen the link between the clinical and surgical management. A second objective was to determine an association between drug-resistant epilepsy and subject gender, the age of first seizure, and the type of seizure. Materials and methods: Over 632 medical records were scrutinized in search of those satisfying the inclusion criteria to end up with a sample of 108 subjects. Neuroimaging specialists reviewed each of the magnetic resonance imaging (MRI) studies looking for abnormalities to make the structural diagnosis and define it. Results: Of the 108 patients included in the study, 51 patients (Group A) were refractory to medical treatment and 57 patients (Group B) showed an improvement with medical treatment. We quantified the frequency of structural lesions confirmed by neuroimaging in both groups. The results showed a statistically significant difference of 84.31% of patients in Group A with a confirmed structural lesion in an MRI study versus 52.63% of patients in Group B (p = 0.004 [odds ratio = 4.85, 95% confidence interval: 2.01-11.66]). Conclusion: Our results support the association between structural lesions diagnosed with MRI and drug-resistant epilepsy. Thus, this finding gives a chance of an opportune and precise approach for the surgical treatment of these patients.

Key words: Epilepsy. Drug-resistant epilepsy. Epilepsy surgery. Epilepsy neuroimaging.

Una relación entre la epilepsia farmacorresistente y las anomalías estructurales en la neuroimagen

Resumen

Antecedentes y objetivos: Buscar una relación entre la epilepsia farmacorresistente y las alteraciones estructurales en la neuroimagen para fortalecer el vínculo entre el manejo clínico y quirúrgico. Un segundo objetivo fue determinar una asociación entre la epilepsia farmacorresistente y el sexo del sujeto, la edad de la primera convulsión y el tipo de crisis epiléptica.

Método: Realizamos un escrutinio de más de 632 registros médicos en busca de aquellos que cumplan con los criterios
**Introducción**

La epilepsia es el trastorno neurológico con la prevalencia más alta en nuestro servicio y una considerable proporción de nuestros pacientes es resistente al tratamiento farmacológico. Hay muchos artículos originales y revisitas que muestran que estos grupos de individuos podrían obtener un beneficio del tratamiento quirúrgico. Los estudios de neuroimagen han ayudado en la localización de posibles zonas resecables.

En 2008, la Liga Internacional contra la Epilepsia (ILAE) definió la epilepsia resistente al tratamiento farmacológico como el trastorno epiléptico con "un fracaso de ensayos clínicos adecuados de dos terapéuticas bien toleradas, aplicadas de manera adecuada y con un anticonvulsivo en combinación" para lograr un control de la epilepsia.

En el 2008, el International League Against Epilepsy (ILAE) definió la resistencia al tratamiento farmacológico como el trastorno epiléptico con "un fracaso de ensayos clínicos adecuados de dos terapéuticas bien toleradas, aplicadas de manera adecuada y con un anticonvulsivo en combinación" para lograr un control de la epilepsia.

En el 2008, el International League Against Epilepsy (ILAE) definió la resistencia al tratamiento farmacológico como el trastorno epiléptico con "un fracaso de ensayos clínicos adecuados de dos terapéuticas bien toleradas, aplicadas de manera adecuada y con un anticonvulsivo en combinación" para lograr un control de la epilepsia.

En el 2008, el International League Against Epilepsy (ILAE) definió la resistencia al tratamiento farmacológico como el trastorno epiléptico con "un fracaso de ensayos clínicos adecuados de dos terapéuticas bien toleradas, aplicadas de manera adecuada y con un anticonvulsivo en combinación" para lograr un control de la epilepsia.

En el 2008, el International League Against Epilepsy (ILAE) definió la resistencia al tratamiento farmacológico como el trastorno epiléptico con "un fracaso de ensayos clínicos adecuados de dos terapéuticas bien toleradas, aplicadas de manera adecuada y con un anticonvulsivo en combinación" para lograr un control de la epilepsia.
for the outcome of the candidates who underwent epilepsy surgery. The majority were retrospective studies and four were clinical trials. Of all the 16,253 candidates, 65% (10,518) had a satisfying outcome\textsuperscript{12}.

Two ECA studies reported by JAMA on 2015 with a total of 118 patients with temporal lobe epilepsy found a higher percentage of seizure free on patients who underwent an epilepsy surgery compared to those who underwent a continuous pharmacologic therapy (58% vs. 8% [\(n = 80\)] and 73% vs. 0% [\(n = 38\)], \(p \leq 0.001\)). The epilepsy surgery was less effective when the lesions were extratemporal when the etiology was not related to a structural abnormality or both. Hippocampal sclerosis and benign brain tumors were associated with better results compared to other pathologies\textsuperscript{13}.

As a result of the failure to control seizures in drug-resistant epilepsy, the risk of premature death increases, quality of life decreases, and it is highly likely that patients with this problem may have an identifiable lesion through an MRI study. Our objective is to determine a relationship between drug-resistant epilepsy and lesions discovery through neuroimaging with the purpose to consider a surgical approach and offer an improved treatment. To prove said relationship, we will analyze the brain MRI studies of a sample of patients with and without the diagnosis of drug-resistant epilepsy with the hope of obtaining and comparing the frequency, in which the structural lesions are present in both types of epilepsies.

### Materials and methods

Subject selection was carried out in the follow-up of patients of the Epilepsy Clinic of the Neurology Service at the Central Hospital "Dr. Ignacio Morones Prieto" by the review of the medical record of all patients with the diagnosis of epilepsy from January 2017 to September 2018 (632 patients). Afterward, we applied the inclusion and exclusion criteria to end up with our final sample (\(n = 108\)) (Table 1). We defined and selected a group of drug-resistant epilepsy patients in accordance with the ILAE criteria (51 subjects). The control group was confirmed by patients with the diagnosis of non-resistant epilepsy (57 subjects) and depending on the age and sex similarities with the group being studied (i.e. the drug-resistant epilepsy group). The diagnosis was supported by a least one electroencephalographic study in all patients. Due to the age group, patients with infantile epileptic syndromes that are resistant to antiepileptic drug treatment were not taken into consideration for this study.

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients older than 15 years of age</td>
<td>Not to having a wish to participate in the study</td>
</tr>
<tr>
<td>Having at least one brain MRI study</td>
<td>Having undergone an epilepsy surgery</td>
</tr>
<tr>
<td>Having at least one EEG confirming the epilepsy diagnosis</td>
<td></td>
</tr>
<tr>
<td>(although the absence of abnormal EEG does not rule out epilepsy, this was an inclusion criterion).</td>
<td></td>
</tr>
<tr>
<td>Meeting the ILAE criteria for drug-resistant epilepsy from Kwan et al., 2010\textsuperscript{14}</td>
<td></td>
</tr>
</tbody>
</table>

All patients were classified according to the either acquired or congenital presence or absence of abnormalities in brain imaging. At the same time, the lesions or malformations were classified in groups: hippocampal sclerosis, cortical development malformation, tumor, neurocysticercosis (NCC)/calcification, stroke, and other causes of minor prevalence.

We used an HD2 G5 1.5 T with an eight-channel neurovascular exploration coil MRI equipment. All available brain imaging studies were included whether they were conducted inside our institution or outside. Analysis of the imaging studies was done by a group of neurologists trained for neuroimaging interpretation and corroborated by a neuroradiologist of the Central Hospital to determine the presence or not of a structural abnormality. Successively, if a lesion was present to clarify which structural lesion was it about. For the diagnosis of hippocampal sclerosis, the increase in T2 signal with changes in fluid-attenuated inversion recovery, the N-acetyl aspartate/(choline + creatinine) index below 0.71, and hippocampal atrophy by comparison between hemispheres in T1 was considered\textsuperscript{15-18}. The most common cortical development malformation found was focal cortical dysplasia, which was diagnosed as cortical thickness changes, effacement of the gray matter-white matter union, and T1 cortical hyperintense signal regarding a normal cortex, while in T2 a radial white matter hyperintense signal beneath the area of the dysplasia\textsuperscript{19}. Stroke lesions were diagnosed with the usual parameters for a chronic ischemic lesion seen as a cavitated cystic encephalomalacia in the area of the old ischemia. As NCC is a prevalent infectious disease on our medium, we decided to include the brain MRI studies displaying the nodular calcified state seen as hypointensities in T1- and T2-weighted image\textsuperscript{20}.

---

\textsuperscript{14}Kwan et al., 2010

\textsuperscript{15}Kwan et al., 2010

\textsuperscript{16}Kwan et al., 2010

\textsuperscript{17}Kwan et al., 2010

\textsuperscript{18}Kwan et al., 2010

\textsuperscript{19}Kwan et al., 2010

\textsuperscript{20}Kwan et al., 2010
**Statistical analysis**

To capture the data, we used a Microsoft Office Excel® (2010) spreadsheet. The variables under study (frequency of drug resistance and neuroimaging confirmed structural lesions) were written down as absolute and relative frequencies. The quantitative variables were kept as means and for determining their dispersion, the standard deviation, the minimum, and maximum were used.

The analysis and realization of graphics were carried out in MegaStat and Microsoft Office Excel®. This analysis was made in parallel with the program SPSS v.18.0. The comparison of categorical variables was made through crosstabs using the Chi-square test or the hypergeometric distribution as appropriate to determine variable independence considering $p < 0.05$ as statistically significant. Similarly, a multivariate analysis and logistic regression were done to establish the attributable risk.

**Protocol approval and ethical aspects**

The realization of this investigation was approved by the Investigation and Ethics Committee of the Central Hospital “Dr. Ignacio Morones Prieto” previous to the start of the medical record selection. All patients gave their consent for the usage, manipulation, and publication of their record data and brain MRI study.

**Results**

We examined 632 medical records with the diagnosis of epilepsy confirmed by electroencephalogram. Only 108 met the inclusion criteria. The main causes of exclusion were the lack of brain imaging, the poor attachment to drug therapy, or being through drug therapy adjustment. Of the 108 patients included in the study, 55 were female (50.92%) and 53 male (49.07%) with an age range from 16 to 72, a mean of 34 years, and a median 30 years.

All the selected candidates were classified in one of two groups. Group A of the drug-resistant epileptic was confirmed by 51 patients (47%) and Group B of the non-drug-resistant epileptic by 57 patients (53%) (Table 2). Four variables were contemplated (age, gender, age of first seizure onset, and type of seizure) for the secondary objective. Of those, only two showed a statistically significant difference between the control group and the drug-resistant group.

We calculated the frequency of structural lesions on neuroimaging depending on the presence or not of abnormalities on the brain. The results reported a statistically significant difference indicating that 84.31% of the patients of Group A showed a structural lesion on MRI compared with the control Group B, in which 52.63% presented a lesion, with $p = 0.004$ (odds ratio = 4.85, 95% confidence interval: 2.01-11.66). This association explains that for every drug-resistant epileptic patient with no evidence of structural lesion, there are almost five patients that do have a lesion (Table 3).

The lesions observed were classified in both groups making a comparative analysis of the frequencies of each group. We noticed that the risk of drug resistance was different between the types of lesion being hippocampal sclerosis the most frequently associated to drug resistance (78.57%) followed by the cortical developmental malformations (60%) (Table 4).

Taking the age of onset into consideration, the subjects who had their first epileptic seizure between the 1st year of age and 5 years had a resistance frequency of 62.5%; in an inverse manner, when the first seizure presented after the 18 years of age, the percentage of resistance decreases 20%. In the in-between group (6-18

---

**Table 2.** Patient demographics Percentage of the frequency of drug-resistant and non-resistant epilepsy with a given variable

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (n = 51) Drug resistant</th>
<th>Group B (n = 57) Non-drug resistant</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>31.8</td>
<td>36.6</td>
<td>0.70</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27 = 52.9%</td>
<td>28 = 49.1%</td>
<td>0.692</td>
</tr>
<tr>
<td>Male</td>
<td>24 = 47.1%</td>
<td>29 = 50.9%</td>
<td></td>
</tr>
<tr>
<td>Age of onset</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 5</td>
<td>20 = 62.5%</td>
<td>12 = 37.5%</td>
<td>0.005</td>
</tr>
<tr>
<td>6 – 18</td>
<td>26 = 51%</td>
<td>25 = 29%</td>
<td></td>
</tr>
<tr>
<td>&gt; 18</td>
<td>5 = 20%</td>
<td>20 = 80%</td>
<td></td>
</tr>
<tr>
<td>Type of seizure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal onset</td>
<td>47 = 92.2%</td>
<td>36 = 63.2%</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Generalized onset</td>
<td>4 = 7.8%</td>
<td>21 = 36.8%</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3.** The frequency of structural lesions on each group

<table>
<thead>
<tr>
<th></th>
<th>Positive for lesion</th>
<th>Negative for lesion</th>
<th>Total</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>43</td>
<td>8</td>
<td>51</td>
<td>84.31</td>
</tr>
<tr>
<td>Group B</td>
<td>30</td>
<td>27</td>
<td>57</td>
<td>52.63</td>
</tr>
<tr>
<td>Total</td>
<td>73</td>
<td>35</td>
<td>108</td>
<td>67.59</td>
</tr>
</tbody>
</table>
years of age), the number of resistant and non-resistant was equivalent (49% vs. 51%, respectively). Hence, there is statistical evidence of an association between the beginning of the seizures at a young age and the probability to develop drug-resistant epilepsy (p = 0.005).

If the seizure onset was focal, then the probability to present drug resistance was higher compared to the generalized onset. In the drug-resistant Group A, there was a high prevalence of focal onset seizures (94%) with only three patients displaying a generalized onset (6%), whereas in the control Group B, 21 patients (36.84%) had a generalized onset and 36 (63.15%) a focal onset (p = 0.0001).

The more used antiepileptic drugs by the patients were carbamazepine (51%), levetiracetam (45%), and valproate (37%). With a minor usage was Lamotrigine (22%) and topiramate (17%), whereas oxcarbazepine, primidone, lacosamide, and phenytoin were the less frequent (<10%). There was not a significant difference in the usage between A and B groups.

### Discussion

The data found supported the relationship between structural lesions observed on an MRI study and drug-resistant epilepsy. However, this affirmation does not mean that any type of lesion could be a risk factor for the development of drug resistance. For this reason, the lesions were classified resulting in hippocampal sclerosis and cortical development malformation occupying the higher percentage of found lesions in the drug-resistant patients.

In particular, the hippocampal sclerosis is the most studied pathology in the epileptic patients and with an excellent success rate after a surgical procedure, having an absence of crisis to almost 70% of the cases and with a low frequency of neurological complications and mortality (< 1%)21.

The age of onset of epileptic seizures appears to be a risk factor for developing drug resistance. The results showed an association curve in which the lower the age of onset the higher the risk of developing drug resistance. This finding is similar to the one reported in a Chinese pediatric sample where it is described that the patients presenting the first seizure in their 1st year of age had a predisposition to develop drug resistance22.

Another fact that supports the final result is the difference found in the type of crisis, where the focal onset was present in 94% of the drug-resistant patients keeping an association with the higher percentage of structural lesions found in this patients compared with the non-drug-resistant ones (84% vs. 52%). This fact was described in a previous study realized in our country23.

There were not effectiveness differences within the variety of AED used as described by the comparisons made by Cochrane studies between the effectiveness of AED in monotherapy24. Even when valproate-lamotrigine combination is considered in those patients with drug resistance, as this therapy has demonstrated to be superior to others in some studies24, in our medium, the patients do not always count with the economic support to acquire this specific AED combination, and in the majority of occasions, the most affordable AED therapy is used.

Stroke is frequently identified as an acute cause of epileptic seizures in adults of < 65 years and 25% of the patients could have drug-resistant epilepsy25. The results we found tell us that 50% of our patients presenting with post-stroke epilepsy had AED resistance. However, we recommend to not consider this percentage due to the few cases we revised (only 10 subjects) and further research is advised.

A study from India indicates that a low proportion of subjects exhibit drug-resistant epilepsy while having an underlying NCC lesion or a cause-effect relationship between an NCC calcification and hippocampal sclerosis26. Another study from Brazil states that NCC alone (or isolated) only counts in a low percentage (1.56%) of the etiologies of drug-resistant epilepsy and that NCC calcification associated lesions account for a higher percentage of the causes (27%). This calcification appears to be deeply correlated with hippocampal sclerosis (p ≤ 0.001)27. All things considered, as our study included a low number of subjects with NCC (nine individuals) and cysticercosis incidence varies depending on the endemicity of each country, we advise not

### Table 4. The frequency of drug resistance in each type of studied lesion

<table>
<thead>
<tr>
<th>Type of lesion</th>
<th>Yes</th>
<th>No</th>
<th>Total</th>
<th>Drug resistance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0. Normal</td>
<td>8</td>
<td>27</td>
<td>35</td>
<td>22.86</td>
</tr>
<tr>
<td>1. Calcifications/NCC</td>
<td>5</td>
<td>4</td>
<td>9</td>
<td>55.56</td>
</tr>
<tr>
<td>2. Hippocampal sclerosis</td>
<td>22</td>
<td>6</td>
<td>28</td>
<td>78.57</td>
</tr>
<tr>
<td>3. Stroke</td>
<td>5</td>
<td>5</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>4. Tumor</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>5. Cortical developmental malformations</td>
<td>6</td>
<td>4</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td>6. Others</td>
<td>5</td>
<td>9</td>
<td>14</td>
<td>35.71</td>
</tr>
</tbody>
</table>
to take for granted our result on infectious etiologies of drug-resistant epilepsy.

In our study, there were included few patients with brain tumors due to not fulfilling the inclusion criteria and the management of the majority of them is in charge of the service of neurosurgery of this institution. For this reason, we could not obtain strong conclusions with respect to this population and recommend further research. Likewise, there were not included patients under the age of 16 that are treated by the service of neuropediatrics.

There is a relationship between the structural lesions seen in MRI study and the probability to develop drug-resistant epilepsy, and this is the reason that for every patient who does not have visible injuries, there are almost five patients who have it.

The risk of resistance is different within the distinct types of lesion, the variety of ages of seizure onset, and the type of onset of the seizure. Hippocampal sclerosis, the early onset of epilepsy and the focal onset seizures are more related to resistance.

Those results allow us to perform an MRI in this type of patient and analyze this study thoroughly and intensely, guided by clinical data in search of lesions, especially in those patients with drug-resistant focal epilepsy. We hope that this sort of study contributes with enough evidence to protocolize this variety of cases and perform a surgical management with a higher frequency and in an opportune and sooner manner on a patient that could potentially and finally benefit from this alternative therapeutic approach.

Conflicts of interest

None of the authors has any conflicts of interest to disclose.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References